uniQure is shrinking again, saying it will shed two-thirds of its staff by the end of the year – about 300 jobs – as it tries to trim $75 million off its annual cash burn.
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to paus
Pfizer has said it will launch its just-approved haemophilia B gene therapy Beqvez with a warranty programme that will provide “greater certainty” to payers, after setting